Inhalations with surfactant-BL in the late respiratory phase of COVID-19 in the patient with a severe course of the disease

Abstract

The patient with severe viral-bacterial pneumonia and verified COVID-19 was successfully treated with surfactant therapy in the late respiratory phase of the disease, surfactant therapy was used to reduce the degree of hypoxemia and accelerate the weaning from non-invasive mechanical ventilation (NIMV). The native surfactant was administered with inhalations at the dose of 75 mg 2times a day on the 5th day of NIMV since SpO2 values persisted to be 92-93% and did not improve. Positive changes were observed after 4 inhalations: SpO2 reached 95% and then remained within the range of 94-97% with FiO2 90%. In total, the patient received 10 inhalations, then she was gradually transferred to breathing through an oronasal mask with humidified oxygen.